• Home
  • Pipeline
    • Inhaled Murepavadin
    • Balixafortide
    • Lonodelestat (external)
  • Breakthrough Platforms
  • Partnering
  • About us
  • Investor Relations
    • Corporate Governance*
    • Reporting*
    • Corporate Presentation
    • Share Information
    • Media Releases
    • Ad-hoc Releases
    • Calendar
    • Contact
  • Careers
  • Contact
    • Home
    • Pipeline
      • Inhaled Murepavadin
      • Balixafortide
      • Lonodelestat (external)
    • Breakthrough Platforms
    • Partnering
    • About us
    • Investor Relations
      • Corporate Governance*
      • Reporting*
      • Corporate Presentation
      • Share Information
      • Media Releases
      • Ad-hoc Releases
      • Calendar
      • Contact
    • Careers
    • Contact
    Spexis
    Spexis
    News
    Menu
    • Home
    • Pipeline
      • Inhaled Murepavadin
      • Balixafortide
      • Lonodelestat (external)
    • Breakthrough Platforms
    • Partnering
    • About us
    • Investor Relations
      • Corporate Governance*
      • Reporting*
      • Corporate Presentation
      • Share Information
      • Media Releases
      • Ad-hoc Releases
      • Calendar
      • Contact
    • Careers
    • Contact
    News
    Menu
    • Mar202017

      March 20-22, 2017: Bio Europe Spring 2017, Barcelona, Spain

      Bio Europe Spring 2017 March 20-22, 2017

      Spexis
      martin halter
    • Previous
    • 1
    • 2
    • 3
    • 4

    News

    • Media releases
    • Ad-hoc releases
    • Conferences & events
    • Publications

    Interact with us

    • Partnering
    • Get our news
    • Join our team

     

    • Contact
    • +41 61 567 16 00
    © 2024, Spexis Ltd., Hegenheimermattweg 125, 4123 Allschwil, Switzerland, T: +41 61 567 16 00, info@spexisbio.com – Disclaimer – Privacy Rules – Disclosure
    This site uses cookies: Find out more.